Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1203mxm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS 15	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 16	FEB 22	Status of current WO (PCT) information on STN
NEWS 17	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 18	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 19	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 20	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 21	FEB 28	TOXCENTER reloaded with enhancements
NEWS 22	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 23	MAR 01	INSPEC reloaded and enhanced
NEWS 24	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 25	MAR 08	X.25 communication option no longer available after June 2006

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:20:22 ON 08 MAR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:20:34 ON 08 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAR 2006 HIGHEST RN 876109-17-0
DICTIONARY FILE UPDATES: 7 MAR 2006 HIGHEST RN 876109-17-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\532958.str



chain nodes :
11 21 22 24 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20
chain bonds :
3-11 4-21 5-22 11-12 24-25 25-26
ring bonds :
1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 13-18
14-15 14-20 15-16 16-17 18-19 19-20
exact/norm bonds :
3-11 11-12 24-25 25-26
exact bonds :
4-21 5-22 13-18 14-20 18-19 19-20
normalized bonds :
1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
isolated ring systems :
containing 1 : 12 :

G1:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sam
SAMPLE SEARCH INITIATED 15:20:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED         1 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.06

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:20:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       45 TO ITERATE

100.0% PROCESSED        45 ITERATIONS                               3 ANSWERS
SEARCH TIME: 00.00.04

L3             3 SEA SSS FUL L1

=> file ca
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'CA' ENTERED AT 15:21:09 ON 08 MAR 2006
```

FILE COVERS 1907 - 2 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 2 Mar 2006 (20060302/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1 L3

=> d ibib abs hitstr

L4 ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 140:406749 CA
TITLE: Preparation of 3-cyanoquinoline derivatives as antitumor agents
INVENTOR(S): Hennequin, Laurent Francois Andre
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041811	A1	20040521	WO 2003-GB4661	20031028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003278369	A1	20040607	AU 2003-278369	20031028
EP 1575943	A1	20050921	EP 2003-769677	20031028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005282856	A1	20051222	US 2005-532958	20050427
PRIORITY APPLN. INFO.:			GB 2002-25579 A	20021102
			WO 2003-GB4661 W	20031028

OTHER SOURCE(S): MARPAT 140:406749
GI



I



II

AB The title compds. [I; Z1 = O, S, SO, SO2, NR2, C(R2)2 (wherein R2 = H, alkyl); m = 0-4; R1 = halo, CF3, CN, etc.; n = 0-3; R3 = halo, CF3, CN, etc.; Z2 = C.tplbond.C, CR13:CR13 (R13 = H, alkyl); R14 = halo, CN, CO2H, etc.], useful in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumor disease, were prepared Thus, reacting [4-(3-methoxyprop-1-ynyl)benzofuran-7-yl]amine with 4-chloro-3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline (prepns. given) in the presence of sodium hexamethyldisilazane in DMF followed by treatment of the crude product with 1M HCl afforded II.HCl. It is believed that the compds. I provide an antitumor effect by way of inhibition of MEK enzymes that are involved in the MAPK kinase pathway and/or by way of inhibition of one or more of the non-receptor tyrosine-specific kinases that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumor cells. For example, the compds. I showed IC50 of < 4 μM in assay to detect MEK inhibition, and IC50 of 0.001-10 μM in in vitro c-Src kinase assay. The pharmaceutical composition comprising the compound I is claimed.

IT **690267-42-6P 690267-43-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-cyanoquinoline derivs. as antitumor agents)

RN 690267-42-6 CA

L4 ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN (Continued)

CN 3-Quinolinecarbonitrile, 6-methoxy-4-[[4-(3-methoxy-1-propynyl)-7-benzofuranyl]amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 690267-43-7 CA
CN 2-Propenoic acid, 3-[7-[(3-cyano-6,7-dimethoxy-4-quinolinyl)amino]-4-benzofuranyl]-, methyl ester (9CI) (CA INDEX NAME)



```
=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.30     172.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.71      -0.71

FILE 'MARPAT' ENTERED AT 15:21:17 ON 08 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE CONTENT: 1969-PRESENT VOL 144 ISS 10 (20060303/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1969-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US   2006014764 19 JAN 2006
DE 202005014897 22 DEC 2005
EP      1609846 28 DEC 2005
JP   2005353222 22 DEC 2005
WO   2006003494 12 JAN 2006
GB      2415429 28 DEC 2005
FR      2871802 23 DEC 2005
RU      2266908 27 DEC 2005
CA      2495134 23 DEC 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

=> s l1 full
FULL SEARCH INITIATED 15:21:20 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -     4496 TO ITERATE

100.0% PROCESSED     4496 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.05

L5            4 SEA SSS FUL L1

=> d ibib abs fqhit 1-4
```

L5 ANSWER 1 OF 4 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 140:406749 MARPAT
TITLE: Preparation of 3-cyanoquinoline derivatives as antitumor agents
INVENTOR(S): Hennequin, Laurent Francois Andre
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041811	A1	20040521	WO 2003-GB4661	20031028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003278369	A1	20040607	AU 2003-278369	20031028
EP 1575943	A1	20050921	EP 2003-769677	20031028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005282856	A1	20051222	US 2005-532958	20050427
PRIORITY APPLN. INFO.:			GB 2002-25579	20021102
			WO 2003-GB4661	20031028

GI

L5 ANSWER 1 OF 4 MARPAT COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. [I; Z1 = O, S, SO, SO2, NR2, C(R2)2 (wherein R2 = H, alkyl); m = 0-4; R1 = halo, CF3, CN, etc.; n = 0-3; R3 = halo, CF3, CN, etc.; Z2 = C.tplbond.C, CR13:CR13 (R13 = H, alkyl); R14 = halo, CN, CO2H, etc.], useful in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumor disease, were prepared Thus, reacting [4-(3-methoxyprop-1-ynyl)benzofuran-7-yl]amine with 4-chloro-3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline (prepns. given) in the presence of sodium hexamethyldisilazane in DMF followed by treatment of the crude product with 1M HCl afforded II.HCl. It is believed that the compds. I provide an antitumor effect by way of inhibition of MEK enzymes that are involved in the MAPK kinase pathway and/or by way of inhibition of one or more of the non-receptor tyrosine-specific kinases that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumor cells. For example, the compds. I showed IC50 of < 4 μM in assay to detect MEK inhibition, and IC50 of 0.001-10 μM in in vitro c-Src kinase assay. The pharmaceutical composition comprising the compound I is claimed.

MSTR 1

L5 ANSWER 1 OF 4 MARPAT COPYRIGHT 2006 ACS on STN (Continued)

G1 = 11



G4 = 6



G22 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G25)
G33 = 23

G41 = 20-11 17-141 18-140 19-173 14-139



Patent location: claim 1
Note: or pharmaceutically acceptable salts or protected derivatives
Note: additional derivatization also claimed
Note: substitution is restricted
Note: also incorporates claim 8

L5 ANSWER 2 OF 4 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 140:357326 MARPAT
TITLE: Preparation of oxazolidin-2-ones as antiasthmatics
INVENTOR(S): Jin, Jian; Kerns, Jeffrey K.; Wang, Feng; Wang, Yonghui
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032856	A2	20040422	WO 2003-US31795	20031007
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-416818P	20021007

GI



I

AB The title compds. [I; n, m = 0-1; p = 1-3; Ar = (un)substituted quinolinyl, [1,5]naphthyridinyl, pyridinyl; R = alkyl, cycloalkylalkyl, phenylalkyl, etc.] which are useful for inhibiting the chemokine receptor nominated CCR8 (no data given), resulting in treatment of diseases such as asthma and the like, were prepared E.g., a 4-step synthesis of 5-(6-methoxyquinolin-4-yl)-3-[1-(naphthalen-2-ylmethyl)piperidin-4-yl]oxazolidin-2-one, starting from 6-methoxy-4-oxiranylquinoline and tert-Bu 4-aminopiperidine-1-carboxylate, was given. The pharmaceutical composition comprising the compound I is claimed.

MSTR 1



L5 ANSWER 2 OF 4 MARPAT COPYRIGHT 2006 ACS on STN (Continued)
G1 = (0-1) CH2
G7 = alkyl <containing 1-6 C> (substd. by G8)
G8 = 214 / 266



G16 = alkyl <containing 1-6 C> / CN
G17 = O
G19 = N
Patent location: claim 1
Note: or pharmaceutically acceptable salts

L5 ANSWER 3 OF 4 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 139:36451 MARPAT
TITLE: Preparation of benzofuranyl substituted 3-cyanoquinolines for the treatment of solid tumors
INVENTOR(S): Hennequin, Laurent Francois Andre; Gibson, Keith Hopkinson; Foote, Kevin Michael
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048159	A1	20030612	WO 2002-GB5493	20021205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002347336	A1	20030617	AU 2002-347336	20021205
PRIORITY APPLN. INFO.:			EP 2001-403124	20011205
			WO 2002-GB5493	20021205

GI

L5 ANSWER 3 OF 4 MARPAT COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. [I; Z = O, S, SO, SO2, etc.; m = 0-4; R1 = halo, CF3, CN, etc.; n = 0-3; R3 = halo, CF3, CN, etc.], useful as an anti-invasive agent in the containment and/or treatment of solid tumor disease, were prepared and formulated. E.g., a multi-step synthesis of II.2HCl, was given. The compds. I showed IC50 in the range 0.001 to 10 μM against c-Src tyrosine kinase (in vitro assay).

MSTR 1



G1 = 11

G4 = 6

L5 ANSWER 3 OF 4 MARPAT COPYRIGHT 2006 ACS on STN (Continued)



G22 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G25)
G33 = 23

Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: additional derivatization also claimed
Note: substitution is restricted
Note: also incorporates claim 11
Stereochemistry: 395 - S

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 4 OF 4 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 139:36446 MARPAT
TITLE: Preparation of benzofuranyl substituted 3-cyanoquinolines for the treatment of solid tumors
INVENTOR(S): Hennequin, Laurent Francois Andre; Gibson, Keith Hopkinson; Poote, Kevin Michael
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047583	A1	20030612	WO 2002-GB5497	20021205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002365665	A1	20030617	AU 2002-365665	20021205
PRIORITY APPLN. INFO.:			EP 2001-403126	20011205
			WO 2002-GB5497	20021205

GI

L5 ANSWER 4 OF 4 MARPAT COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. [I; Z = O, S, SO, SO2, etc.; m = 0-4; R1 = halo, CF3, CN, etc.; n = 0-3; R3 = halo, CF3, CN, etc.], useful as an anti-proliferative agent in the containment and/or treatment of solid tumor disease, were prepared and formulated. E.g., a multi-step synthesis of II.2HCl, was given. The compds. I tested had IC50 of < 0.5 μM in assay to detect MEK inhibition.

MSTR 1



G4 = 6

L5 ANSWER 4 OF 4 MARPAT COPYRIGHT 2006 ACS on STN (Continued)



G22 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G25)
G33 = 23

Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: additional derivatization also claimed
Note: substitution is restricted

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 15:20:22 ON 08 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 15:20:34 ON 08 MAR 2006
L1              STRUCTURE UPLOADED
L2            0 S L1 SAM
L3            3 S L1 FULL

     FILE 'CA' ENTERED AT 15:21:09 ON 08 MAR 2006
L4            1 S L3

     FILE 'MARPAT' ENTERED AT 15:21:17 ON 08 MAR 2006
L5            4 S L1 FULL

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY    SESSION
FULL ESTIMATED COST                               136.51     308.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                  ENTRY    SESSION
CA SUBSCRIBER PRICE                                -2.84      -3.55

STN INTERNATIONAL LOGOFF AT 15:21:59 ON 08 MAR 2006
```